Adaptive Biotechnologies (ADPT) Cash & Current Investments (2018 - 2026)

Adaptive Biotechnologies has reported Cash & Current Investments for 9 years, with the latest figure at $218.3 million in Q1 2026.

• Quarterly Cash & Current Investments rose 12.88% year-over-year to $218.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.3 million (up 12.88% YoY) and the FY2025 annual result came in at $227.0 million, up 2.11% from the prior year.
• Cash & Current Investments declined to $218.3 million in Q1 2026 per ADPT's latest filing, from $227.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $508.1 million in Q3 2022 and troughed at $193.4 million in Q1 2025.
• A 5-year average of $320.3 million and a median of $308.9 million in 2024 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 41.11% in 2022, down 49.1% in 2022.
• Over 5 years, Cash & Current Investments stood at $498.2 million in 2022, then tumbled by 30.47% to $346.4 million in 2023, then slumped by 35.83% to $222.3 million in 2024, then gained by 2.11% to $227.0 million in 2025, then declined by 3.81% to $218.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $218.3 million, $227.0 million, and $212.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.